sino biopharmaceutical ltd. - SBHMY

SBHMY

Close Chg Chg %
9.05 -0.72 -7.90%

Closed Market

8.34

-0.72 (7.90%)

Volume: 161.00

Last Updated:

Dec 16, 2024, 3:37 PM EDT

Company Overview: sino biopharmaceutical ltd. - SBHMY

SBHMY Key Data

Open

$8.34

Day Range

8.34 - 8.34

52 Week Range

6.69 - 9.65

Market Cap

$7.62B

Shares Outstanding

916.86M

Public Float

N/A

Beta

0.49

Rev. Per Employee

N/A

P/E Ratio

21.94

EPS

$1.64

Yield

128.04%

Dividend

$0.07

EX-DIVIDEND DATE

Sep 11, 2024

SHORT INTEREST

N/A

AVERAGE VOLUME

20.67

 

SBHMY Performance

1 Week
 
-7.90%
 
1 Month
 
4.19%
 
3 Months
 
13.63%
 
1 Year
 
-19.66%
 
5 Years
 
N/A
 

SBHMY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About sino biopharmaceutical ltd. - SBHMY

Sino Biopharmaceutical Ltd. is an investment holding company, which engages in the manufacture and sale of pharmaceutical products. It operates through the following business segments: Investment, Modernised Chinese Medicines and Chemical Medicines; and Others. The Investment segment offers long-term investments. The Modernised Chinese Medicines and Chemical Medicines segment comprises the manufacturing, selling, and distribution of modernized Chinese medicine products and western medicine products. The Investment segment offers long-term investments. The Other segment includes a research and development sector, which provides services to third parties; and related healthcare and hospital business. It also develops medicines for treating tumors, analgesia, diabetes, and respiratory system diseases. The company was founded by Ping Tse Cheung Ling Cheng and on February 2, 2000, and is headquartered in Hong Kong.

SBHMY At a Glance

Sino Biopharmaceutical Ltd.
Office Tower
Hong Kong,
Phone 852-2802-9886 Revenue 3.70B
Industry Pharmaceuticals: Major Net Income 329.14M
Sector Health Technology Employees 25,806
Fiscal Year-end 12 / 2024
View SEC Filings

SBHMY Valuation

P/E Current 21.937
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 25.016
Price to Sales Ratio 2.227
Price to Book Ratio 1.945
Price to Cash Flow Ratio 8.822
Enterprise Value to EBITDA 9.766
Enterprise Value to Sales 2.526
Total Debt to Enterprise Value 0.192

SBHMY Efficiency

Revenue/Employee 143,294.392
Income Per Employee 12,754.249
Receivables Turnover 4.231
Total Asset Turnover 0.407

SBHMY Liquidity

Current Ratio 1.053
Quick Ratio 0.965
Cash Ratio 0.556

SBHMY Profitability

Gross Margin 80.954
Operating Margin 22.013
Pretax Margin 22.656
Net Margin 8.901
Return on Assets 2.936
Return on Equity 6.225
Return on Total Capital 4.383
Return on Invested Capital 5.691

SBHMY Capital Structure

Total Debt to Total Equity 41.728
Total Debt to Total Capital 29.442
Total Debt to Total Assets 19.993
Long-Term Debt to Equity 4.505
Long-Term Debt to Total Capital 3.178
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sino Biopharmaceutical Ltd. - SBHMY

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
3.43B 4.16B 4.27B 3.70B
Sales Growth
-2.31% +21.57% +2.62% -13.48%
Cost of Goods Sold (COGS) incl D&A
750.82M 826.76M 860.67M 704.28M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
233.28M 150.61M 149.67M 142.47M
Depreciation
122.66M 136.67M 134.57M 127.07M
Amortization of Intangibles
110.62M 13.94M 15.10M 15.40M
COGS Growth
+5.31% +10.12% +4.10% -18.17%
Gross Income
2.68B 3.34B 3.41B 2.99B
Gross Income Growth
-4.26% +24.78% +2.25% -12.30%
Gross Profit Margin
+78.08% +80.15% +79.86% +80.95%
2020 2021 2022 2023 5-year trend
SG&A Expense
2.06B 2.54B 2.49B 2.18B
Research & Development
380.56M 570.17M 631.62M 621.45M
Other SG&A
1.68B 1.97B 1.86B 1.56B
SGA Growth
+0.04% +23.17% -1.93% -12.52%
Other Operating Expense
- - - -
-
Unusual Expense
(75.02M) 103.47M 62.35M 20.12M
EBIT after Unusual Expense
687.59M 694.14M 859.42M 793.88M
Non Operating Income/Expense
86.02M 119.98M 86.66M 113.79M
Non-Operating Interest Income
28.11M 25.13M 29.92M 26.35M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
46.85M 47.85M 65.20M 69.90M
Interest Expense Growth
+40.78% +2.14% +36.26% +7.20%
Gross Interest Expense
46.85M 47.85M 65.20M 69.90M
Interest Capitalized
- - - -
-
Pretax Income
726.76M 766.26M 880.88M 837.77M
Pretax Income Growth
-10.06% +5.43% +14.96% -4.89%
Pretax Margin
+21.21% +18.40% +20.61% +22.66%
Income Tax
97.41M 303.58M 115.24M 112.53M
Income Tax - Current - Domestic
120.25M 114.85M 115.49M 85.86M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(22.84M) 188.73M (253.35K) 26.67M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
628.88M 2.58B 742.92M 651.04M
Minority Interest Expense
227.40M 311.10M 365.18M 384.09M
Net Income
401.48M 2.27B 377.74M 266.95M
Net Income Growth
+2.49% +464.19% -83.32% -29.33%
Net Margin Growth
+11.72% +54.38% +8.84% +7.22%
Extraordinaries & Discontinued Operations
- - - 62.19M
-
Discontinued Operations
- - - 62.19M
-
Net Income After Extraordinaries
401.48M 2.27B 377.74M 329.14M
Preferred Dividends
- - - -
-
Net Income Available to Common
401.48M 2.27B 377.74M 329.14M
EPS (Basic)
0.4271 2.4137 0.4057 0.3553
EPS (Basic) Growth
+2.55% +465.14% -83.19% -12.42%
Basic Shares Outstanding
940.01M 938.43M 931.11M 926.45M
EPS (Diluted)
0.4271 2.2717 0.3973 0.3553
EPS (Diluted) Growth
+2.55% +431.89% -82.51% -10.57%
Diluted Shares Outstanding
940.01M 964.15M 950.86M 926.45M
EBITDA
845.85M 948.22M 1.07B 956.47M
EBITDA Growth
-11.35% +12.10% +12.99% -10.73%
EBITDA Margin
+24.69% +22.77% +25.07% +25.87%

Sino Biopharmaceutical Ltd. in the News